Table 2.
CAPRIE—Primary Efficacy Analysis Stratified by PPI Type Using Various Definitions for PPI Treatment
| Subgroup | Clopidogrel, n (%) | Aspirin, n (%) | Unadjusted Estimated HR (95% CI) | P Value for Interaction | |
|---|---|---|---|---|---|
| Baseline PPI use | |||||
| Any PPI | No (n=18 967) | 926 (9.8) | 1015 (10.7) | 0.90 (0.83 to 0.99) | 0.047 |
| Yes (n=218) | 13 (11.7) | 5 (4.7) | 2.66 (0.94 to 7.50) | ||
| Omeprazole | No (n=18 969) | 926 (9.8) | 1016 (10.7) | 0.90 (0.83 to 0.99) | 0.027 |
| Yes (n=216) | 13 (11.8) | 4 (3.8) | 3.37 (1.09 to 10.4) | ||
| Lansoprazole | No (n=19 183) | 939 (9.8) | 1019 (10.6) | 0.91 (0.84 to 1.00) | N/A |
| Yes (n=2) | 0 | 1 (100) | N/A | ||
| Concomitant PPI use | |||||
| Any PPI | No (n=18 316) | 884 (9.6) | 975 (10.7) | 0.89 (0.81 to 0.98) | 0.019 |
| Yes (n=869) | 55 (13.8) | 45 (9.6) | 1.41 (0.95 to 2.09) | ||
| Omeprazole | No (n=18 340) | 884 (9.6) | 976 (10.7) | 0.89 (0.81 to 0.98) | 0.015 |
| Yes (n=845) | 55 (14.1) | 44 (9.6) | 1.44 (0.96 to 2.14) | ||
| Lansoprazole | No (n=19 148) | 938 (9.8) | 1018 (10.6) | 0.91 (0.84 to 1.00) | 0.774 |
| Yes (n=37) | 1 (6.7) | 2 (9.1) | 0.58 (0.05 to 6.43) | ||
| Any PPI use | |||||
| Any PPI | No (n=18 298) | 882 (9.6) | 975 (10.7) | 0.89 (0.81 to 0.97) | 0.011 |
| Yes (n=887) | 57 (14.0) | 45 (9.4) | 1.46 (0.99 to 2.16) | ||
| Omeprazole | No (n=18 322) | 882 (9.6) | 976 (10.7) | 0.89 (0.81 to 0.97) | 0.009 |
| Yes (n=863) | 57 (14.3) | 44 (9.5) | 1.49 (1.00 to 2.21) | ||
| Lansoprazole | No (n=19 148) | 938 (9.8) | 1018 (10.6) | 0.91 (0.84 to 1.00) | 0.774 |
| Yes (n=37) | 1 (6.7) | 2 (9.1) | 0.58 (0.05 to 6.43) | ||
CAPRIE indicates Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events; PPI, proton pump inhibitor; HR, hazard ratio; N/A, not available.